Company news
Arbutus Biopharma Corporation (NASDAQ:ABUS) news
Every Arbutus Biopharma Corporation press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases — page 2
Arbutus Reports Second Quarter 2023 Financial Results and Corporate Update
August 3, 2023
Arbutus to Report Second Quarter 2023 Financial Results and Provide Corporate Update
July 20, 2023
Arbutus Appoints Melissa V. Rewolinski, PhD to its Board of Directors
July 12, 2023
Arbutus Appoints Two New Executives
July 10, 2023
Arbutus Presents Preliminary AB-729 and Pegylated Interferon Alfa-2a Combination Data at the EASL Congress 2023
June 21, 2023
Arbutus Doses First Patient in Additional Treatment Arm of Phase 2a Triple Combination Clinical Trial that Includes a PD-1 Monoclonal Antibody
June 21, 2023
Arbutus to Present AB-729 and AB-836 Data at EASL Congress 2023
June 7, 2023
Arbutus to Present at Jefferies Healthcare Conference
May 31, 2023
Arbutus to Present at JMP Securities Life Sciences Conference
May 9, 2023
Arbutus Reports First Quarter 2023 Financial Results and Corporate Update
May 4, 2023
Arbutus Provides AB-729 Clinical Data and AB-161 Preclinical Data as Oral Presentations at the Global Hepatitis Summit 2023
April 27, 2023
Arbutus Announces FDA Clinical Hold on IND Application for AB-101, an oral PD-L1 inhibitor
April 25, 2023
Arbutus to Report First Quarter 2023 Financial Results and Provide Corporate Update
April 20, 2023
Arbutus to Present AB-729 and AB-161 Data at the Global Hepatitis Summit 2023
April 18, 2023
Arbutus Biopharma and Genevant Sciences File Patent Infringement Lawsuit Against Pfizer/BioNTech
April 4, 2023
Arbutus Doses First Subject in Phase 1 Clinical Trial with its Oral RNA Destabilizer, AB-161
March 16, 2023
Arbutus Presents AB-343 Data at the 36th International Conference on Antiviral Research
March 14, 2023
Arbutus Reports Fourth Quarter and Year End 2022 Financial Results and Corporate Update
March 2, 2023
Arbutus to Report Fourth Quarter and Year End 2022 Financial Results and Provide Corporate Update
February 16, 2023
Arbutus to Participate in Three Upcoming Investor Conferences
February 6, 2023
Arbutus Announces Resignation of Board Member
January 27, 2023
Arbutus Announces 2023 Corporate Objectives and Provides Financial Update
January 5, 2023
Arbutus Completes Enrollment in its Phase 2a Clinical Trial Combining AB-729 with NA Therapy and Peginterferon alfa-2a in Patients with Chronic Hepatitis B Virus Infection
December 13, 2022
Arbutus Reports Third Quarter 2022 Financial Results and Provides Corporate Update
November 9, 2022
Arbutus Presents AB-729 Clinical Data and AB-101 Preclinical Data at AASLD - The Liver Meeting®
November 1, 2022
Arbutus Announces Three Poster Presentations with Clinical Data from AB-729 and Preclinical Data from AB-101 at AASLD - The Liver Meeting® 2022
October 31, 2022
Arbutus to Report Third Quarter 2022 Financial Results and Provide Corporate Update
October 26, 2022
Gaston Picchio, PhD, Chief Development Officer, to Depart Arbutus at Year End
September 30, 2022
Arbutus to Present at Chardan’s 6th Annual Genetic Medicines Conference
September 22, 2022
Arbutus to Participate in September Investor Conferences
September 6, 2022
Arbutus Biopharma Announces Issuance of a New Key U.S. Patent Related to AB-729
August 30, 2022
Arbutus Reports Second Quarter 2022 Financial Results and Provides Corporate Update
August 4, 2022
Arbutus to Report Second Quarter 2022 Financial Results and Provide Corporate Update
July 21, 2022
Arbutus Biopharma Provides Update on the Phase 2A Combination Trial with AB-729 and a Capsid Inhibitor
July 20, 2022
Arbutus Presents New Data on AB-729, AB-836 and AB-101 at the EASL International Liver Congress™ 2022 and Provides AB-836 Clinical Update
June 25, 2022
Arbutus to Present Seven Scientific Posters at EASL International Liver Congress™ 2022
June 6, 2022
Arbutus and Vaccitech Dose First Patient in Phase 2a Clinical Trial Combining Therapies for the Treatment of Chronic Hepatitis B Virus
June 6, 2022
Arbutus to Participate in June Investor Conferences
June 2, 2022
Arbutus Announces Abstract Selected for Publication at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
May 26, 2022
Arbutus to Present at H.C. Wainwright Global Investment Conference
May 17, 2022
Arbutus Reports First Quarter 2022 Financial Results and Provides Corporate Update
May 5, 2022
Arbutus to Report First Quarter 2022 Financial Results and Provide Corporate Update
April 21, 2022
Arbutus Reports Fourth Quarter and Year End 2021 Financial Results and Provides Corporate Update
March 3, 2022
Genevant Sciences and Arbutus Biopharma File Patent Infringement Lawsuit Against Moderna
February 28, 2022
Arbutus Biopharma and Genevant Sciences File Patent Infringement Lawsuit Against Moderna
February 28, 2022
Arbutus to Report Fourth Quarter and Year End 2021 Financial Results and Provide Corporate Update
February 17, 2022
Arbutus Announces 2022 Corporate Objectives and Provides Financial Update
January 24, 2022
Arbutus to Participate at H.C. Wainwright Bioconnect Virtual Conference
January 4, 2022
Antios Therapeutics and Arbutus Biopharma Announce First Patient Dosed in Phase 2a Combination Trial of ATI-2173, AB-729 and Tenofovir Disoproxil Fumarate in Patients with Chronic Hepatitis B Virus Infection
December 14, 2021
Arbutus and Qilu Pharmaceutical Enter into an Exclusive Licensing Agreement and Strategic Partnership to Develop and Commercialize AB-729 in mainland China, Hong Kong, Macau and Taiwan
December 13, 2021